First Time Loading...

Beam Therapeutics Inc
NASDAQ:BEAM

Watchlist Manager
Beam Therapeutics Inc Logo
Beam Therapeutics Inc
NASDAQ:BEAM
Watchlist
Price: 22.74 USD -3.11% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

BEAM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. [ Read More ]

The intrinsic value of one BEAM stock under the Base Case scenario is 6.4 USD. Compared to the current market price of 22.74 USD, Beam Therapeutics Inc is Overvalued by 72%.

Key Points:
BEAM Intrinsic Value
Base Case
6.4 USD
Overvaluation 72%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Beam Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BEAM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Beam Therapeutics Inc

Provide an overview of the primary business activities
of Beam Therapeutics Inc.

What unique competitive advantages
does Beam Therapeutics Inc hold over its rivals?

What risks and challenges
does Beam Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Beam Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Beam Therapeutics Inc.

Provide P/S
for Beam Therapeutics Inc.

Provide P/E
for Beam Therapeutics Inc.

Provide P/OCF
for Beam Therapeutics Inc.

Provide P/FCFE
for Beam Therapeutics Inc.

Provide P/B
for Beam Therapeutics Inc.

Provide EV/S
for Beam Therapeutics Inc.

Provide EV/GP
for Beam Therapeutics Inc.

Provide EV/EBITDA
for Beam Therapeutics Inc.

Provide EV/EBIT
for Beam Therapeutics Inc.

Provide EV/OCF
for Beam Therapeutics Inc.

Provide EV/FCFF
for Beam Therapeutics Inc.

Provide EV/IC
for Beam Therapeutics Inc.

Show me price targets
for Beam Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Beam Therapeutics Inc?

How accurate were the past Revenue estimates
for Beam Therapeutics Inc?

What are the Net Income projections
for Beam Therapeutics Inc?

How accurate were the past Net Income estimates
for Beam Therapeutics Inc?

What are the EPS projections
for Beam Therapeutics Inc?

How accurate were the past EPS estimates
for Beam Therapeutics Inc?

What are the EBIT projections
for Beam Therapeutics Inc?

How accurate were the past EBIT estimates
for Beam Therapeutics Inc?

Compare the revenue forecasts
for Beam Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Beam Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Beam Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Beam Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Beam Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Beam Therapeutics Inc with its peers.

Analyze the financial leverage
of Beam Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Beam Therapeutics Inc.

Provide ROE
for Beam Therapeutics Inc.

Provide ROA
for Beam Therapeutics Inc.

Provide ROIC
for Beam Therapeutics Inc.

Provide ROCE
for Beam Therapeutics Inc.

Provide Gross Margin
for Beam Therapeutics Inc.

Provide Operating Margin
for Beam Therapeutics Inc.

Provide Net Margin
for Beam Therapeutics Inc.

Provide FCF Margin
for Beam Therapeutics Inc.

Show all solvency ratios
for Beam Therapeutics Inc.

Provide D/E Ratio
for Beam Therapeutics Inc.

Provide D/A Ratio
for Beam Therapeutics Inc.

Provide Interest Coverage Ratio
for Beam Therapeutics Inc.

Provide Altman Z-Score Ratio
for Beam Therapeutics Inc.

Provide Quick Ratio
for Beam Therapeutics Inc.

Provide Current Ratio
for Beam Therapeutics Inc.

Provide Cash Ratio
for Beam Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Beam Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Beam Therapeutics Inc?

What is the current Free Cash Flow
of Beam Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Beam Therapeutics Inc.

Financials

Balance Sheet Decomposition
Beam Therapeutics Inc

Current Assets 1.2B
Cash & Short-Term Investments 1.2B
Other Current Assets 21.2m
Non-Current Assets 248.7m
PP&E 237.8m
Other Non-Current Assets 10.9m
Current Liabilities 205.6m
Accounts Payable 1.6m
Accrued Liabilities 124m
Other Current Liabilities 80m
Non-Current Liabilities 272.8m
Other Non-Current Liabilities 272.8m
Efficiency

Earnings Waterfall
Beam Therapeutics Inc

Revenue
377.7m USD
Operating Expenses
-554.2m USD
Operating Income
-176.5m USD
Other Expenses
44m USD
Net Income
-132.5m USD

Free Cash Flow Analysis
Beam Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BEAM Profitability Score
Profitability Due Diligence

Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
27/100
Profitability
Score

Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

BEAM Solvency Score
Solvency Due Diligence

Beam Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
52/100
Solvency
Score

Beam Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BEAM Price Targets Summary
Beam Therapeutics Inc

Wall Street analysts forecast BEAM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BEAM is 51 USD with a low forecast of 27.27 USD and a high forecast of 81.9 USD.

Lowest
Price Target
27.27 USD
20% Upside
Average
Price Target
51 USD
124% Upside
Highest
Price Target
81.9 USD
260% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BEAM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BEAM Price
Beam Therapeutics Inc

1M 1M
-33%
6M 6M
+18%
1Y 1Y
-25%
3Y 3Y
-72%
5Y 5Y
+21%
10Y 10Y
+21%
Annual Price Range
22.74
52w Low
17.69
52w High
45.07
Price Metrics
Average Annual Return 95.88%
Standard Deviation of Annual Returns 216.02%
Max Drawdown -87%
Shares Statistics
Market Capitalization 1.9B USD
Shares Outstanding 82 702 302
Percentage of Shares Shorted 20.88%

BEAM Return Decomposition
Main factors of price return

What is price return decomposition?

BEAM News

Last Important Events
Beam Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Beam Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Beam Therapeutics Inc Logo
Beam Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.9B USD

Dividend Yield

0%

Description

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. The company is headquartered in Cambridge, Massachusetts and currently employs 341 full-time employees. The company went IPO on 2020-02-06. The firm is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. The firm has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301.

Contact

MASSACHUSETTS
Cambridge
26 Landsdowne St
+18573278775.0
https://beamtx.com/

IPO

2020-02-06

Employees

341

Officers

CEO & Director
Mr. John M. Evans M.B.A.
President
Dr. Giuseppe Ciaramella Ph.D.
CFO & Treasurer
Ms. Terry-Ann Burrell M.B.A.
Co-Founder
Dr. Alexis Komor Ph.D.
Chief Technology Officer
Dr. Manmohan Singh Ph.D.
Chief Scientific Officer
Dr. Gopi Shanker Ph.D.

See Also

Discover More
What is the Intrinsic Value of one BEAM stock?

The intrinsic value of one BEAM stock under the Base Case scenario is 6.4 USD.

Is BEAM stock undervalued or overvalued?

Compared to the current market price of 22.74 USD, Beam Therapeutics Inc is Overvalued by 72%.